Nyxoah Appoints John Landry as Chief Financial Officer

Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company’s focus on the U.S. market.

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch.

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States.

Route 92 Medical Announces Appointment of Chris Hartman as Chief Commercial Officer

SAN MATEO, Calif., July 10, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Chris Hartman to the role of Chief Commercial Officer. In this role, Chris will be responsible for continuing to build the sales and marketing organizations to grow Route 92 Medical’s global commercial footprint.

Akura Medical, A Shifamed Portfolio Company, Appoints Murali Srivathsa as President and CEO

CAMPBELL, Calif., April 19, 2022 /PRNewswire/ --  Akura Medical, Inc., a Shifamed portfolio company, announced today that seasoned medtech executive, Murali Srivathsa, has joined as President and CEO. With over two decades of industry experience, Murali brings a wealth of medical device and senior leadership expertise. He joins as the team finalizes product development of its next-generation thrombectomy device.

one8o° Placement Round-Up

one8o° is thrilled to announce the following placements in the first quarter of 2022:

• Murali Srivathsa - CEO, Akura Medical

• Michael Pereira - COO, Beta Bionics

• Todd Goede - VP, Research & Developement, Artelon

We wish our partners continued success and look forward to watching these companies make important impacts on the medtech industry.

Berkshire Biomedical Appoints John E. Timberlake as CEO

DALLAS, April 27, 2021 /PRNewswire/ -- Berkshire Biomedical, LLC ("Berkshire" or "the Company"), a privately-held digital health company developing a revolutionary virtual care prescription drug delivery and management system only for the Intended User, today announced the appointment of John E. Timberlake as President and Chief Executive Officer.

Cardiovascular Systems, Inc. Announces Sachin H. Jain, MD, MBA, Joins Board of Directors

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Sachin H. Jain, MD, MBA.

Cardiovascular Systems, Inc. Announces Kelvin Womack Joins Board of Directors

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Kelvin Womack.

CorVent Medical Appoints Richard S. Walsh as Chief Executive Officer

NEW YORK CITY, NY, August 4, 2020 – CorVent Medical, a Coridea portfolio company focused on developing smart, versatile, lifesaving ventilators for critical care, announced today the appointment of Richard S. Walsh to Chief Executive Officer (CEO). Mr. Walsh comes with almost three decades in the industry, both with start-ups and large, global organizations, and brings a wealth of medtech and senior leadership experience. He joins CorVent as the team prepares to commercialize its RESPOND-19™ ventilator and position the company as an innovator in reliable, lifesaving ventilators that efficiently address overflow ventilation needs.

ChroniSense Medical Appoints appoints Bridget Ross as Chief Executive Officer (CEO)

March 19, 2020 – ChroniSense Medical, developer of Polso™, a wearable, medical-grade, disease management device for multiple clinical applications, announced the appointment of Bridget Ross as Chief Executive Officer (CEO) effective February 10, 2020.

Ablative Solutions Appoints Kate Rumrill as President and Chief Executive Officer

San Jose, Calif. -- July 11 2019 -- Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced that Kate Rumrill has been appointed as the new President and CEO. Rumrill will also serve on the board of directors for the company. With 30 years industry experience, Rumrill brings deep expertise in delivering products to market from both the pharmaceutical and medical device industries.

iRhythm Technologies Names Karim Karti as Chief Operating Officer

SAN FRANCISCO, June 27, 2018 (GLOBE NEWSWIRE) – iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the appointment of Karim Karti to Chief Operating Officer effective July 23, 2018. Karti brings more than 20 years of experience and a proven track record of driving growth, profitability and innovation in the global health care technology and services industry…

Avedro Names Jim Schuermann as Chief Business Officer

WALTHAM, Mass.–(BUSINESS WIRE)–Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that James F. Schuermann has joined the company as Chief Business Officer (CBO). Mr. Schuermann will lead the global government affairs, health economics and reimbursement, communications, sales, field service, marketing and business development functions and will report to Avedro’s Chief Executive Officer, Reza Zadno…

Procyrion Names Elisabeth Neely Senior Vice President of Clinical and Regulatory Affairs, Formerly with Abbott

Houston, Texas (March 21, 2018) – Procyrion, Inc., a clinical-stage medical device company developing the first catheter-deployed, intra-aortic pump for ambulatory use, AortixTM, today announced the appointment of Elisabeth (Beth) Neely, RAC, as Senior Vice President of Clinical and Regulatory Affairs. In this role, Neely will proactively develop, lead and drive the execution of a global regulatory and clinical strategy with a focus on efficient, rapid and timely approval of the novel Aortix device…

Relievant Appoints Christopher Geyen Chief Financial Officer

SUNNYVALE, Calif., March 06, 2018 (GLOBE NEWSWIRE) — Relievant Medsystems, a privately held medical device company that has developed the Intracept® Procedure, a minimally invasive and clinically proven approach for the treatment of chronic low back pain, announced today the appointment of Christopher Geyen as Chief Financial Officer.  Mr. Geyen will report to Relievant’s Chief Executive Officer, Kevin Hykes.

Respicardia Announces First U.S. Commercial Case with the remedē® System; Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch

MINNETONKA, Minn., Feb. 2, 2018 /PRNewswire/ — Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first U.S. commercial case using the remedē® System to treat central sleep apnea was completed at The Ohio State University Wexner Medical Center in Columbus, Ohio by Ralph Augostini, MD, FACC, FHRS, Bob and Corrine Frick Chair in Cardiac Electrophysiology, Associate Professor of Medicine and co-director of the electrophysiology training program. The first case coincides with the naming of season medical device executive, Peter Sommerness, as CEO of Respicardia and the leader of the remedē® system U.S. launch…

Tryton Medical Announces New CEO and President

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company has appointed Carl J. St. Bernard as president and chief executive officer…

Vascular Dynamics Appoints Ed Roschak CEO

MOUNTAIN VIEW, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc. (VDI), a privately held medical device company which has developed an innovative treatment system for the treatment of hypertension, today announced the appointment of Mr. Ed Roschak as its president and chief executive officer.